メンタル失調の最新研究の紹介|TMS for Resistant Depression: at 12 months, 68% of patients achieved symptomatic improvement(15/02/13)
トップページ > メンタル失調の最新研究の紹介|TMS for Resistant Depression: at 12 months, 68% of patients achieved symptomatic improvement(15/02/13)

メンタル失調の最新研究の紹介|TMS for Resistant Depression: at 12 months, 68% of patients achieved symptomatic improvement(15/02/13)

2015年02月13日(金)9:30 PM

PARAGON LLCis famous for Recent studies have shown that at 12 months, 68% of patients achieved symptomatic improvement, and 45% reported complete remission with TMS.
Maintenance of benefit was observed under a pragmatic regimen of continuation antidepressant medication and access to TMS reintroduction for symptom recurrence.

These recent study on TMS are very important and exciting study. Several prior studies have shown that prefrontal rTMS works to treat depression acutely.
Until these recent study only limited information about how well these patients do a year after completing a course of TMS.
Long-term data following remission produced by medications or electroconvulsive therapy [ECT] in these treatment-resistant patients have been disappointing, with only about 13% being still remitted a year later.
For example, over half of patients who remit with ECT are ill again 6 months later.
Thus, having 45% in remission a full year later is very, very encouraging that rTMS is perhaps changing the underlying pathological circuitry associated with depression and producing a more stable remission than the other treatments.
This is great news for our field of psychiatry and for the millions of patients who suffer from depression and do not respond well to medications.

045



«   |   »


合同会社 パラゴン
モバイルサイト